Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent

Prostate

Volumn 72, Issue 16, 2012, Pages 1767-1778

  Lin, Hsiang Yu ^a,b,c   Kuo, Yi Chiu ^a   Weng, Yu I ^a   Lai, I Lu ^a   Huang, Tim H M ^a   Lin, Shuan Pei ^c   Niu, Dau Ming ^b,d   Chen, Ching Shih ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

DNA methyltransferases; energy restriction; energy restriction mimetic agent; epigenetics; prostate cancer

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; CALVASCULIN; CG 5; DEOXYGLUCOSE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; GLUCOSE; GLUTATHIONE PEROXIDASE 3; GLUTATHIONE TRANSFERASE P1; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HERMES ANTIGEN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ANAEROBIC GLYCOLYSIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL STRAIN LNCAP; CELL VIABILITY; DNA METHYLATION; ENERGY METABOLISM; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE SILENCING; HISTONE MODIFICATION; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PYROSEQUENCING; RNA INTERFERENCE; TRANSCRIPTION INITIATION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL LINE, TUMOR; DEOXYGLUCOSE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; TRANSCRIPTIONAL ACTIVATION;

EID: 84867884641     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22530     Document Type: Article

References (40)

1. Kroemer G, Pouyssegur J,. Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell 2008; 13 (6): 472-482.
2. Vander Heiden MG,. Targeting cancer metabolism: A therapeutic window opens. Nat Rev Drug Discov 2011; 10 (9): 671-684.
3. Denko NC,. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8 (9): 705-713.
4. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB,. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004; 64 (11): 3892-3899.
5. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, Xu Y, Wonsey D, Lee LA, Dang CV,. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000; 275 (29): 21797-21800.
6. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM,. p53 regulates mitochondrial respiration. Science 2006; 312 (5780): 1650-1653.
7. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'Shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC,. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005; 11 (8): 2785-2808.
8. Wei S, Kulp SK, Chen CS,. Energy restriction as an antitumor target of thiazolidinediones. J Biol Chem 2010; 285 (13): 9780-9791.
9. Chen CH, Huang PH, Chu PC, Chen MC, Chou CC, Wang D, Kulp SK, Teng CM, Wang Q, Chen CS,. Energy restriction-mimetic agents induce apoptosis in prostate cancer cells in part through epigenetic activation of KLF6 tumor suppressor gene expression. J Biol Chem 2011; 286 (12): 9968-9976.
10. Sharma S, Kelly TK, Jones PA,. Epigenetics in cancer. Carcinogenesis 2010; 31 (1): 27-36.
11. Tost J, Gut IG,. DNA methylation analysis by pyrosequencing. Nat Protoc 2007; 2 (9): 2265-2275.
12. Ibragimova I, Ibanez de Caceres I, Hoffman AM, Potapova A, Dulaimi E, Al-Saleem T, Hudes GR, Ochs MF, Cairns P,. Global reactivation of epigenetically silenced genes in prostate cancer. Cancer Prev Res (Phila) 2010; 3 (9): 1084-1092.
13. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON,. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci USA 2008; 105 (52): 20882-20887.
14. Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, Konig H, Weg-Remers S, Ponta H,. CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann NY Acad Sci 2000; 910: 106-118; discussion 118-120.
15. Li F, Tiede B, Massague J, Kang Y,. Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res 2007; 17 (1): 3-14.
16. Hartl M, Nist A, Khan MI, Valovka T, Bister K,. Inhibition of Myc-induced cell transformation by brain acid-soluble protein 1 (BASP1). Proc Natl Acad Sci USA 2009; 106 (14): 5604-5609.
17. Zerbini LF, Libermann TA,. GADD45 deregulation in cancer: Frequently methylated tumor suppressors and potential therapeutic targets. Clin Cancer Res 2005; 11 (18): 6409-6413.
18. Qiu W, David D, Zhou B, Chu PG, Zhang B, Wu M, Xiao J, Han T, Zhu Z, Wang T, Liu X, Lopez R, Frankel P, Jong A, Yen Y,. Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma. Am J Pathol 2003; 162 (6): 1961-1974.
19. Yu YP, Yu G, Tseng G, Cieply K, Nelson J, Defrances M, Zarnegar R, Michalopoulos G, Luo JH,. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res 2007; 67 (17): 8043-8050.
20. Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M, Chow NH, Grasso M, Wu L, Westra WB, Sidransky D,. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 2001; 7 (9): 2727-2730.
21. Massoner P, Colleselli D, Matscheski A, Pircher H, Geley S, Jansen Durr P, Klocker H,. Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: Inhibition of proliferation, adhesion, and motility. Endocr Relat Cancer 2009; 16 (3): 795-808.
22. Mehta H, Gao Q, Galet C, Paharkova V, Wan J, Said JW, Sohn J, Lawson G, Cohen P, Cobb L, Lee KW,. IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res 2011; 71 (15): 5154-5163.
23. Sathyanarayana UG, Padar A, Suzuki M, Maruyama R, Shigematsu H, Hsieh JT, Frenkel EP, Gazdar AF,. Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2003; 9 (17): 6395-6400.
24. Vanaja DK, Grossmann ME, Cheville JC, Gazi MH, Gong A, Zhang JS, Ajtai K, Burghardt TP, Young CY,. PDLIM4, an actin binding protein, suppresses prostate cancer cell growth. Cancer Invest 2009; 27 (3): 264-272.
25. Boye K, Maelandsmo GM,. S100A4 and metastasis: A small actor playing many roles. Am J Pathol 2010; 176 (2): 528-535.
26. Li Q, Ahuja N, Burger PC, Issa JP,. Methylation and silencing of the thrombospondin-1 promoter in human cancer. Oncogene 1999; 18 (21): 3284-3289.
27. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, Jacob ST,. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 2005; 25 (11): 4727-4741.
28. Patel K, Dickson J, Din S, Macleod K, Jodrell D, Ramsahoye B,. Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res 2010; 38 (13): 4313-4324.
29. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD,. DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 2008; 28 (2): 752-771.
30. Fang Y, Brass A, Hoyle DC, Hayes A, Bashein A, Oliver SG, Waddington D, Rattray M,. A model-based analysis of microarray experimental error and normalisation. Nucleic Acids Res 2003; 31 (16): e96. http://www.ncbi.nlm.nih. gov/pubmed/12907748
31. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caligiuri MA, Chan KK, Wu LC, Marcucci G,. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008; 111 (4): 2364-2373.
32. Kimura H, Nakamura T, Ogawa T, Tanaka S, Shiota K,. Transcription of mouse DNA methyltransferase 1 (Dnmt1) is regulated by both E2F-Rb-HDAC-dependent and -independent pathways. Nucleic Acids Res 2003; 31 (12): 3101-3113.
33. Yang CC, Wang YC, Wei S, Lin LF, Chen CS, Lee CC, Lin CC,. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation. Cancer Res 2007; 67 (7): 3229-3238.
34. Ohtani K, DeGregori J, Nevins JR,. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA 1995; 92 (26): 12146-12150.
35. Ma Y, Yuan J, Huang M, Jove R, Cress WD,. Regulation of the cyclin D3 promoter by E2F1. J Biol Chem 2003; 278 (19): 16770-16776.
36. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang LS, Yang Q, Huang J,. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 2009; 69 (7): 787-798.
37. Dejeux E, El abdalaoui H, Gut IG, Tost J,. Identification and quantification of differentially methylated loci by the pyrosequencing technology. Methods. Mol Biol 2009; 507: 189-205.
38. Li LC, Carroll PR, Dahiya R,. Epigenetic changes in prostate cancer: Implication for diagnosis and treatment. J Natl Cancer Inst 2005; 97 (2): 103-115.
39. Park JY,. Promoter hypermethylation in prostate cancer. Cancer Control 2010; 17 (4): 245-255.
40. Issa JP, Kantarjian HM,. Targeting DNA methylation. Clin Cancer Res 2009; 15 (12): 3938-3946.